Business Wire

SK Capital Completes Strategic Investment in Ecopol

14.9.2023 07:30:00 EEST | Business Wire | Press release

Share

Ecopol S.p.A. (“Ecopol” or the “Company”), a leading developer and producer of innovative biodegradable films and delivery systems, announced today the completion of a strategic investment from affiliates of SK Capital Partners, LP (“SK Capital”), a leading private investment firm focused on the specialty materials, ingredients, and life sciences sectors. SK Capital has acquired a majority interest in the Company with Mauro Carbone, Ecopol’s CEO and controlling shareholder, retaining a significant stake and remaining as both the CEO and largest individual shareholder. It is also announced the formation of a new Board of Directors, which includes industry leaders with extensive experience across sustainable materials and consumer packaged goods (“CPG”) markets in Ecopol’s value chains, including Jan-Dirk Auris, E. Craig Mitchell, Daniele Ferrari and Dave Mezzanotte.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913054522/en/

“Ecopol is pleased to begin our partnership with SK Capital and to be working with a diverse team of high-impact industry executives who have joined our Board of Directors,” said Mauro Carbone, Ecopol CEO. “I am excited for the next chapter of our journey as we work together to accelerate Ecopol’s rapid growth and continue to make strategic investments to provide even greater value for our global customer base and bring more sustainable solutions to both existing and new markets. We are grateful to Roberto Quagliuolo, Luca Bucelli and Laurent Labatut for their contributions as former Board Directors and look forward to Tikehau Capital’s continued support as an ongoing minority shareholder.”

“In partnership with Mauro, we have assembled a world-class Board of Directors who will be highly impactful in helping Ecopol execute its strategic priorities and achieve its vision to become the global leader in highly innovative and sustainable delivery systems,” added Stephen D’Incelli, Managing Director at SK Capital. “We look forward as a Board to supporting Mauro and his leadership team in driving Ecopol’s next phase of transformational growth.”

In connection with the closing, SK Capital and Mauro have appointed the following Board Directors:

Jan-Dirk Auris spent over 35 years at Henkel AG & Co. KGaA (“Henkel”), where he served in a variety of senior executive roles and as a member of the Henkel Management Board. He most recently led Henkel’s Adhesives Technologies business unit, where he had extensive experience serving leading global CPG companies. Mr. Auris played a leading role in implementing a new performance management playbook across Henkel and driving innovation and sustainability initiatives.

E. Craig Mitchell has over 35 years of experience in the specialty materials industry and currently serves as President, Flavors and Extracts Group at Sensient Technologies Corporation. He previously served in critical roles at global leaders in Ecopol’s supply chain, including President and COO of Sekisui Specialty Chemicals America, LLC, a manufacturer of polyvinyl alcohol, as well as VP of Sales, Americas of Celanese Corporation, a producer of vinyl acetate monomer.

Daniele Ferrari will serve as Board Chairman. Mr. Ferrari, who is based full-time in Italy, has over 35 years of experience in the specialty materials industry, most recently as the CEO of Versalis S.p.A., the largest chemical company in Italy, and as Chairman of Matrìca S.p.A., a joint-venture with Novamont, a leader in the bio-plastics industry at the forefront of renewable chemistry. Mr. Ferrari has served as a Senior Director at SK Capital and brings significant sustainability leadership in prior roles as President of the European Chemical Industry Council (“CEFIC”), President of Plastics Europe, and as a board member of the Alliance to End Plastics Waste.

Dave Mezzanotte has over 40 years of experience in the specialty materials and packaging industries and has served as a Senior Director at SK Capital since 2018. He previously was Chairman and CEO of Coveris, a global manufacturer of flexible consumer packaging, and CEO of CHEP, a global logistics services provider for CPGs.

The Board of Directors also includes Mauro Carbone, Ecopol CEO and significant minority investor; Stephen d’Incelli, Deal Lead and Managing Director at SK Capital; and Josh Lieberman, Principal at SK Capital.

Latham & Watkins LLP served as legal counsel to SK Capital. Lead arrangers and bookrunners Crédit Agricole Italia S.p.A. and Intesa Sanpaolo S.p.A provided committed financing in support of the transaction. Legance and Alpeggiani Studio Legale Associato served as legal counsel and STS Deloitte served as tax advisor to Ecopol. UBS served as financial advisor.

About Ecopol

Ecopol is a leading global producer of water-soluble and biodegradable films. The Company’s innovative delivery systems for unit-dose applications allow the world’s leading brands to significantly reduce CO2 emissions and the usage of water and virgin plastic throughout their supply chains. Headquartered in Chiesina Uzzanese, Tuscany, Ecopol operates production campuses in Italy and the United States, providing the highest levels of service, technical support and innovation partnership to its worldwide customer base. For more information, please visit www.ecopol.com.

About SK Capital

SK Capital is a private investment firm with a disciplined focus on the specialty materials, ingredients and life sciences sectors. The firm seeks to build resilient, sustainable and growing businesses that create substantial long-term economic value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability, as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $17 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries. The firm currently has approximately $7.8 billion in assets under management. For more information, please visit www.skcapitalpartners.com.

About Tikehau Capital

Tikehau Capital is a global alternative asset management group with €41.1 billion of assets under management (as of 30 June 2023). Tikehau Capital has developed a wide range of expertise across four asset classes (private debt, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Leveraging its strong equity base (€3.1 billion of shareholders’ equity as of 30 June 2023), the firm invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 742 employees (as of 30 June 2023) across its 15 offices in Europe, the Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit www.tikehaucapital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jeremy Milner
BackBay Communications
jeremy.milner@backbaycommunications.com
(401) 862-9422

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release

LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye